Amphastar P (AMPH)
Cash conversion cycle
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Days of inventory on hand (DOH) | days | 131.72 | 145.88 | 144.30 | 150.26 | 151.16 | 150.19 | 143.97 | 142.04 | 142.31 | 157.39 | 163.69 | 163.56 | 171.15 | 201.29 | 195.64 | 207.93 | 211.79 | 205.17 | 184.01 | 146.97 |
Days of sales outstanding (DSO) | days | 65.11 | 72.23 | 70.66 | 70.83 | 64.96 | 58.04 | 61.85 | 58.68 | 65.70 | 69.05 | 64.53 | 77.27 | 68.86 | 56.68 | 54.49 | 64.45 | 51.38 | 50.26 | 54.99 | 63.43 |
Number of days of payables | days | 31.66 | 42.41 | 25.97 | 31.86 | 29.92 | 29.04 | 45.31 | 35.59 | 34.06 | 34.01 | 46.39 | 38.72 | 43.05 | 42.84 | 40.55 | 31.81 | 48.03 | 41.17 | 58.34 | 64.10 |
Cash conversion cycle | days | 165.16 | 175.70 | 188.99 | 189.22 | 186.20 | 179.19 | 160.51 | 165.13 | 173.95 | 192.43 | 181.83 | 202.11 | 196.96 | 215.13 | 209.58 | 240.57 | 215.14 | 214.26 | 180.66 | 146.31 |
December 31, 2023 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= 131.72 + 65.11 – 31.66
= 165.16
The cash conversion cycle of Amphastar Pharmaceuticals Inc has shown fluctuations over the past eight quarters, ranging from 160.51 days to 189.22 days. A lower cash conversion cycle indicates that the company is efficient in managing its working capital, while a higher cycle suggests inefficiencies in converting inventory and receivables into cash.
In Q2 2022, the company had the lowest cash conversion cycle of 160.51 days, indicating a more efficient cash management system during that period. However, in Q2 2023 and Q1 2023, the cash conversion cycle increased significantly to 188.99 days and 189.22 days, respectively, indicating potential issues with the company's ability to convert its investments in inventory and receivables into cash.
It is important for Amphastar Pharmaceuticals Inc to monitor and manage its cash conversion cycle effectively to ensure optimal working capital management and liquidity. By analyzing the factors contributing to the fluctuations in the cycle, the company can identify areas for improvement in its cash flow operations.
Peer comparison
Dec 31, 2023